Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594334 | 1.00 | MAPK14 (0.59) | MAPK14KDM4EALDH1A1HSD17B10PKM | |
| SCHEMBL4380849 | 0.91 | MAPK14 (0.58) | MAPK14KDM4EALDH1A1HSD17B10PKM | |
| Trifluoroacetic Acid SCHEMBL4489690 | 0.84 | MAPK14 (0.52) | MAPK14KDM4EALDH1A1HSD17B10VNN1 | |
| SCHEMBL3522226 | 0.84 | MAPK14 (0.51) | MAPK14KDM4EALDH1A1HSD17B10PKM | |
| SCHEMBL4379238 | 0.82 | MAPK14 (0.57) | MAPK14KDM4EALDH1A1HSD17B10PKM | |
| SCHEMBL4374522 | 0.75 | MAPK14 (0.63) | MAPK14ALDH1A1BRD4 | |
| SCHEMBL29594345 | 0.74 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4384361 | 0.74 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL3523258 | 0.74 | MAPK14 (0.50) | MAPK14KDM4EALDH1A1HSD17B10VNN1 | |
| SCHEMBL6473452 | 0.72 | VNN1 (0.45) | MAPK14KDM4EVNN1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | claimed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| CN-111601593-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2020-08-28 | — | — | CN | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885KDM4E 1129/4885ALDH1A1 4699/4885 |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | MAPK14 193/4885KDM4E 1355/4885ALDH1A1 4642/4885 |
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MAPK14 41/4885KDM4E 3869/4885ALDH1A1 787/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885KDM4E 1129/4885ALDH1A1 4699/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 53/4885KDM4E 3921/4885ALDH1A1 741/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885KDM4E 1129/4885ALDH1A1 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.